<DOC>
	<DOCNO>NCT03067883</DOCNO>
	<brief_summary>To evaluate efficacy safety Ombitasvir , paritaprevir , ritonavir plus ribavirin base therapy chronic hepatitis C without compensate cirrhosis haemodialysis patient .</brief_summary>
	<brief_title>Efficacy Safety Qurevo Plus Ribavirin Based Therapy Hepatitis C With Without Cirrhosis Haemodialysis Patients</brief_title>
	<detailed_description>The aim study ; To evaluate efficacy safety ombitasvir , paritaprevir , ritonavir base therapy chronic hepatitis C without compensate cirrhosis HCV treatment naïve patient receive long-term haemodialysis assessment : 1 . The proportion patient sustain virological response ( HCV RNA &lt; 25 IU/mL ) 12 week last dose study drug ( SVR12 ) . 2 . To determine withdrawal rate relate side effect /or adverse effect patient receive least 1 dose study medication .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<criteria>1 . Under regular HD least 6 month 2 . Clinically stable condition outpatient . 3 . Treatment naïve patient serum positive HCV GT4 HCV RNA &gt; 1000 IU/ml PCR . 4 . White blood cell count &gt; 2500/mm^3 . 5 . Platelet count &gt; 7500/mm^3 . 6 . Patients categorise compensated cirrhosis diagnosis cirrhosis base previous screen liver FibroTest score 0·72 low ( eg , Metavir Fibrosis Score &gt; 3 [ include 3/4 34 ] ) . 1 . Confirmed pregnancy . 2 . HCVHIV co infection . 3 . HBVHCV co infection . 4 . Uncontrolled hyper hypothyroidism . 5 . For patient without cirrhosis , Patients exclude alanine aspartate aminotransferase five time upper limit normal , patient cirrhosis exclude alanine aspartate aminotransferase high seven time upper limit normal 6 . Patients peritoneal dialysis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>